Loading stock data…
REGN
$701.42-5.64 (-0.80%)
Market ClosedLast close May 1
Regeneron Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regeneron Pharmaceuticals, Inc. in the Healthcare sector is trading at $701.42. The stock is currently 15% below its 52-week high of $821.11, remaining 2.8% above its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why REGN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$701.42
Potential Upside
15.9%
Whystock Fair Value$813.24
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$875.31+24.8%
Range$730.00 – $1057
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$78.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.99
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Strong income play. Yield provides a meaningful total return floor.
50.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.26%
Volume
Today's trading volume
728,877
Recent News
1 Cash-Producing Stock Worth Investigating and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the most profitable biotech stocks to buy now. On April 10, Piper Sandler reaffirmed an Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with a $875 price target. The assessment followed an Integrated Oncology Day event at the Sylvester Cancer Center in Miami. The event included discussions on oncology therapies […]
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment.
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
Investors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.
Regeneron's Eylea Franchise on 'Solid Footing' Despite HD Sales Miss in Q1, Oppenheimer Says
Regeneron Pharmaceuticals' (REGN) Q1 results reflected mixed trends, as weaker-than-expected sales o